Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
Standard
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. / Nabergoj, Mitja; Mauff, Katya; Robin, Marie; Kröger, Nicolaus; Angelucci, Emanuele; Poiré, Xavier; Passweg, Jakob; Radujkovic, Aleksandar; Platzbecker, Uwe; Robinson, Stephen; Rambaldi, Alessandro; Petersen, Søren Lykke; Stölzel, Fridrich; Stelljes, Matthias; Ciceri, Fabio; Mayer, Jiri; Ladetto, Marco; de Wreede, Liesebeth C; Koster, Linda; Hayden, Patrick J; Czerw, Tomasz; Hernández-Boluda, Juan Carlos; McLornan, Donal; Chalandon, Yves; Yakoub-Agha, Ibrahim.
In: BONE MARROW TRANSPL, Vol. 56, No. 8, 08.2021, p. 1944-1952.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT
AU - Nabergoj, Mitja
AU - Mauff, Katya
AU - Robin, Marie
AU - Kröger, Nicolaus
AU - Angelucci, Emanuele
AU - Poiré, Xavier
AU - Passweg, Jakob
AU - Radujkovic, Aleksandar
AU - Platzbecker, Uwe
AU - Robinson, Stephen
AU - Rambaldi, Alessandro
AU - Petersen, Søren Lykke
AU - Stölzel, Fridrich
AU - Stelljes, Matthias
AU - Ciceri, Fabio
AU - Mayer, Jiri
AU - Ladetto, Marco
AU - de Wreede, Liesebeth C
AU - Koster, Linda
AU - Hayden, Patrick J
AU - Czerw, Tomasz
AU - Hernández-Boluda, Juan Carlos
AU - McLornan, Donal
AU - Chalandon, Yves
AU - Yakoub-Agha, Ibrahim
N1 - © 2021. The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/8
Y1 - 2021/8
N2 - Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.
AB - Therapeutic management of patients with primary or secondary myelofibrosis (MF) who experience relapse or graft failure following allogeneic haematopoietic cell transplantation (allo-HCT) remains heterogeneous. We retrospectively analyzed 216 patients undergoing a second allo-HCT for either relapse (56%) or graft failure (31%) between 2010 and 2017. Median age was 57.3 years (range 51-63). The same donor as for the first allo-HCT was chosen in 66 patients (31%) of whom 19 received an HLA-identical sibling donor, whereas a different donor was chosen for 116 patients (54%). Median follow-up was 40 months. Three-year overall survival (OS) and relapse-free survival (RFS) were 42% and 39%, respectively. Three-year non-relapse mortality (NRM) and relapse rates were 36% and 25%, respectively. Grade II-IV and III-IV acute GVHD occurred in 25% and 11% of patients, respectively, and the 3-year incidence of chronic GVHD was 33% including 14% for extensive grade. Graft-failure incidence at 1 year was 14%. In conclusion, our data suggest that a second allo-HCT is a potential option for patients failing first allo-HCT for MF albeit careful patient assessment is fundamental to identify individual patients who could benefit from this approach.
U2 - 10.1038/s41409-021-01271-4
DO - 10.1038/s41409-021-01271-4
M3 - SCORING: Journal article
C2 - 33824436
VL - 56
SP - 1944
EP - 1952
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 8
ER -